Has Qelbree (viloxazine) been FDA-approved for ADHD?
Yes. Qelbree, the brand name for viloxazine, has FDA approval for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in certain pediatric and adult patients. (The specific age groups and dosing details are set by the FDA label.) [1]
What is FDA approval for Qelbree based on?
FDA approval for Qelbree is based on clinical evidence showing that viloxazine improves ADHD symptoms compared with placebo in the studied populations, as reflected in the FDA-approved prescribing information. [1]
What are the key details patients and prescribers look for in the FDA label?
The FDA label is where you’ll find the specifics that matter most in practice, including:
- Approved age groups for use
- Dosing and titration approach
- Safety warnings and common adverse reactions
- How to monitor patients during treatment [1]
Where to verify the current FDA approval status and label language
For the most up-to-date confirmation of FDA approval and the prescribing information, check the FDA-approved label and the official FDA materials for Qelbree. [1]
How does viloxazine compare with other non-stimulant ADHD options?
Qelbree (viloxazine) is a non-stimulant option. If you’re comparing it to other ADHD medications, the most relevant factors usually include onset/titration, side-effect profile, comorbidities (like anxiety or sleep issues), and whether it’s used as first-line vs after stimulant trials. Those specifics depend on the individual medication’s FDA label.
Patent and market exclusivity notes (if you’re researching availability)
For market research around patents and exclusivity that can affect when competitors (or generics) might enter, DrugPatentWatch.com tracks relevant IP filings and timelines. [2]
Sources:
1. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. https://www.drugpatentwatch.com/